Illumina Net Income 2006-2021 | ILMN

Illumina annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Illumina net income for the quarter ending September 30, 2021 was $0.317B, a 77.09% increase year-over-year.
  • Illumina net income for the twelve months ending September 30, 2021 was $906M, a 42.01% increase year-over-year.
  • Illumina annual net income for 2020 was $0.656B, a 34.53% decline from 2019.
  • Illumina annual net income for 2019 was $1.002B, a 21.31% increase from 2018.
  • Illumina annual net income for 2018 was $0.826B, a 13.77% increase from 2017.
Illumina Annual Net Income
(Millions of US $)
2020 $656
2019 $1,002
2018 $826
2017 $726
2016 $463
2015 $462
2014 $353
2013 $125
2012 $151
2011 $87
2010 $125
2009 $72
2008 $39
2007 $-287
2006 $40
2005 $-21
Illumina Quarterly Net Income
(Millions of US $)
2021-09-30 $317
2021-06-30 $185
2021-03-31 $147
2020-12-31 $257
2020-09-30 $179
2020-06-30 $47
2020-03-31 $173
2019-12-31 $239
2019-09-30 $234
2019-06-30 $296
2019-03-31 $233
2018-12-31 $210
2018-09-30 $199
2018-06-30 $209
2018-03-31 $208
2017-12-31 $68
2017-09-30 $163
2017-06-30 $128
2017-03-31 $367
2016-12-31 $124
2016-09-30 $129
2016-06-30 $120
2016-03-31 $90
2015-12-31 $105
2015-09-30 $118
2015-06-30 $102
2015-03-31 $137
2014-12-31 $153
2014-09-30 $93
2014-06-30 $47
2014-03-31 $60
2013-12-31 $81
2013-09-30 $31
2013-06-30 $36
2013-03-31 $-23
2012-12-31 $72
2012-09-30 $30
2012-06-30 $23
2012-03-31 $26
2011-12-31 $12
2011-09-30 $20
2011-06-30 $31
2011-03-31 $24
2010-12-31 $38
2010-09-30 $35
2010-06-30 $30
2010-03-31 $21
2009-12-31 $12
2009-09-30 $17
2009-06-30 $25
2009-03-31 $19
2008-12-31 $26
2008-09-30 $-10
2008-06-30 $13
2008-03-31 $11
2007-12-31 $-13
2007-09-30 $15
2007-06-30 $9
2007-03-31 $-298
2006-12-31 $17
2006-09-30 $16
2006-06-30 $7
2006-03-31 $-0
2005-12-31 $0
2005-09-30 $-1
2005-06-30 $-19
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $63.323B $3.239B
Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69